Uterine Neoplasms clinical trials
The registry lists 248 studies for Uterine Neoplasms across more than 10 countries. 59 are recruiting or about to start. 44 of them are mainly about Uterine Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-12. Counting its 4 narrower conditions too, such as Uterine Cervical Neoplasms: 3,607 studies, 1,079 open.
Get an email when these change. Save the Uterine Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
M.D. Anderson Cancer Center (15) · Memorial Sloan Kettering Cancer Center (10) · University of Alabama at Birmingham (5) · University Health Network, Toronto (4) · Dana-Farber Cancer Institute (4) · National Cancer Institute (NCI) (4) · Washington University School of Medicine (4) · Northwestern University (4)
What is being tested here
Drugs under test in Uterine Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cisplatin | 3 | 0 | 4 |
| Paclitaxel | 1 | 0 | 10 |
| Doxorubicin | 1 | 0 | 2 |
| Fluorouracil | 1 | 0 | 2 |
| Leucovorin | 1 | 0 | 2 |
| Oxaliplatin | 1 | 0 | 2 |
| Coenzyme Q10 | 1 | 0 | 1 |
| Tisotumab vedotin | 1 | 0 | 1 |
| Rinatabart sesutecan | 1 | 0 | 1 |
| Zanzalintinib | 1 | 0 | 1 |
Drug classes tested here Tyrosine kinase inhibitors (TKIs) 3 open · Antibody-drug conjugates (ADCs) 3 open · Immune checkpoint inhibitors 2 open · Antimitotic agents 1 open · Antimetabolites 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
The 10 nearest, phase 3 first
- Oct 2027Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) · Phase 3 · AstraZeneca
- Nov 2026PROton Therapy for Post Surgical Treatment of GYNecologic Cancer · Abramson Cancer Center at Penn Medicine
- Dec 2026Image-Guided Gynecologic Brachytherapy · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Dec 2026Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic Surgery · Stanford University
- Dec 2026Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic Pathology · ZIWIG
- Dec 2026Diagnostic Value of Transcervical True-Cut Biopsy in Uterine Masses · Assiut University
- Dec 2026Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin · Dana-Farber Cancer Institute
- Dec 2026Radiomics and Molecular Classification in Endometrial Cancer · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
- Dec 2026Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers · Emory University
- Dec 2026With Love, Grandma ("Con Cariño, Abuelita") Pilot Study · University of Miami Sylvester Comprehensive Cancer Center
Who these studies take
Of the 49 Uterine Neoplasms studies recruiting now, 38 (78%) set no upper age limit and 6 (12%) stop at 75 or younger. 2 (4%) take children under 18. 36 (73%) are for women only and 0 (0%) for men only; 5 (10%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 2 (4%) | 2 (4%) |
| 18 | 43 (88%) | 13 (27%) |
| 30 | 46 (94%) | 13 (27%) |
| 40 | 47 (96%) | 13 (27%) |
| 50 | 47 (96%) | 13 (27%) |
| 65 | 47 (96%) | 13 (27%) |
| 75 | 46 (94%) | 13 (27%) |
| 85 | 42 (86%) | 13 (27%) |
Across all 248 studies, recruiting or not: 9% stop at 75 or younger and 5% at 65; 8% take children; 69% are for women only and <1% for men only; 8% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Uterine Neoplasms studies take
Of 41 interventional studies with no phase under Uterine Neoplasms, half reached primary completion within 28 months of starting, counting those still running.
| Start to primary completion | Every sponsor | Industry | Non-industry |
|---|---|---|---|
| Interventional, no phase | 28 mo15–71 · 41 studies | — | 28 mo15–71 · 40 studies |
| Observational | 66 mo35–174 · 39 studies | — | — |
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 14, 2026.
Started recruiting1
Newly registered2
Studies
Recruiting first, then most recently updated. Showing 50 of 248. Browse all 248 → or search them.
- Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical CancerRecruitingNCT06952660Phase 42 countries
- Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)RecruitingNCT05579366Phase 1/24 countries
- Comparison of Superficial-Only Versus Combined Indocyanine Green Injection Techniques for Sentinel Lymph Node Mapping in Patients With Endometrial CancerNot yet recruitingNCT07916610Not applicable
- A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid MalignanciesRecruitingNCT07542704Phase 11 country
- Radiotherapy for Gynecologic Cancer With Up to 10 Active Metastatic LesionsRecruitingNCT078837981 country
- Reirradiation and Total Ablative Strategies for Recurrent Gynecologic CancerRecruitingNCT076671921 country
- Alternate Day Fasting After Surgery for Patients Undergoing ChemotherapyRecruitingNCT05990426Not applicable1 country
- Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine CancerRecruitingNCT06795009Phase 11 country
- DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial CancerRecruitingNCT06989112Phase 323 countries
- COQ10 and Vitamin E for Off-Target Radiation ToxicityNot yet recruitingNCT07668284Phase 1/21 country
- Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial CancersRecruitingNCT050495381 country
- Tissue Acquisition and Genomics Analysis of Breast Cancer and Other Gynecologic MalignanciesEnrolling by invitationNCT037627331 country
- Liquid Biopsy Evaluation and Repository Development at Princess MargaretRecruitingNCT037023091 country
- Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial CancerRecruitingNCT07831902Phase 31 country
- Artificial Intelligence Into Ultrasound Diagnostics in Reproductive MedicineRecruitingNCT078109201 country
- Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer PatientsRecruitingNCT04038619Phase 11 country
- PROton Therapy for Post Surgical Treatment of GYNecologic CancerRecruitingNCT05758688Phase 21 country
- Sentinel Node Biopsy in Endometrial CancerRecruitingNCT04073706Phase 37 countries
- Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological CancersRecruitingNCT06492070Phase 21 country
- PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric CancerRecruitingNCT04329494Phase 11 country
- Investigations of Reproductive Cancers in WomenRecruitingNCT065271571 country
- Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial CancerRecruitingNCT06040970Phase 1/21 country
- Hypofractionated RadiochemotherapyRecruitingNCT06331468Phase 21 country
- Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)RecruitingNCT07044336Phase 328 countries
- A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF AlterationsRecruitingNCT05503797Phase 212 countries
- Initial Testing of a Behavioral Intervention About Genetic Services for Families at Risk of Lynch SyndromeRecruitingNCT07106359Not applicable1 country
- Evaluation of Interactions and Group Processes in Multidisciplinary Tumor Boards in Gynecologic OncologyNot yet recruitingNCT076457161 country
- [18F]FES PET/.CT in Uterine CancerRecruitingNCT05916196Phase 21 country
- Performance of SYMMCORA® vs. V-Loc® Suture Material in Patients Undergoing Laparoscopic Total HysterectomyRecruitingNCT060241092 countries
- Measurement of Urinary Hormones in Patients With Abnormal Uterine Bleeding to Study Uterine Cancer ProgressionNot yet recruitingNCT075812881 country
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingNCT05559879Phase 1/21 country
- Assessment of Sexual Quality of Life Following Local Treatment (Radiotherapy With or Without Surgery) in Patients With HPV-positive Pelvic Cancer: a Descriptive Longitudinal StudyNot yet recruitingNCT07523152Not applicable
- Cancer Loyalty Card Study 2 (CLOCS-2)RecruitingNCT064470641 country
- Trans-Rectal Ultrasound of the Female Pelvis for Real-Time MRI-US Fusion Based Needle TrackingRecruitingNCT059776211 country
- Azenosertib in Uterine Serous Carcinoma: Biomarker StudyRecruitingNCT06369155Phase 21 country
- With Love, Grandma ("Con Cariño, Abuelita") Pilot StudyRecruitingNCT05721976Not applicable1 country
- Prospective Cohort Study of Minimal Residual Disease(MRD) Testing for Early Recurrence Detection in Endometrial and Cervical CancerNot yet recruitingNCT073825051 country
- Validation of a Lab-free Low-cost Screening Test for Prevention of Cervical CancerRecruitingNCT06815939Not applicable1 country
- Sample Collection for Ongoing Research and Product Evaluation StudyRecruitingNCT073180511 country
- Prognostic Role of molEcular classiFication in Fertility-sparing treAtment of Endometrial canCErNot yet recruitingNCT067996241 country
- Image-Guided Gynecologic BrachytherapyRecruitingNCT02993900Not applicable1 country
- Diagnostic Value of Transcervical True-Cut Biopsy in Uterine MassesNot yet recruitingNCT07264660
- Molecular and Cellular Profiling of Uterine Lavage Collected During Gynecologic SurgeryRecruitingNCT07044505Not applicable1 country
- Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic OriginRecruitingNCT06677190Phase 21 country
- Ultrasound Transformation of Myomas During Relugolix-Estradiol-Norethisterone Treatment: The MySaturn StudyRecruitingNCT069530761 country
- NYSCF Scientific Discovery BiobankRecruitingNCT062031061 country
- Evaluation of Salivary RNA in Subjects Scheduled for Surgery for a Gynecologic PathologyRecruitingNCT063929971 country
- Analysis and Optimization of Predictive and Therapeutic Models in Uterine NeoplasmsRecruitingNCT036247121 country
- Research Project on Reminders and Self-Sampling Can Increase Participation in Gynecology Cell Sampling - Preventive Examination Against Cervical Cancer.RecruitingNCT04061967Not applicable1 country
- Evaluation of Toxicity and Outcomes of Different Therapeutic Strategies in Patients With Uterine NeoplasmsRecruitingNCT067744821 country